Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | OPRM1 | P35372 | 13/20 | 0.49 |
| ▸ | OPRK1 | P41145 | 12/20 | 0.49 |
| ▸ | DRD1 | P21728 | 1/20 | 0.46 |
| ▸ | GNRHR | P30968 | 1/20 | 0.46 |
| ▸ | MRGPRX2 | Q96LB1 | 1/20 | 0.46 |
| ▸ | ABCB11 | O95342 | 1/20 | 0.45 |
| ▸ | CAPN1 | P07384 | 2/20 | 0.44 |
| ▸ | NMUR2 | Q9GZQ4 | 2/20 | 0.43 |
| ▸ | NMUR1 | Q9HB89 | 2/20 | 0.43 |
| ▸ | APLNR | P35414 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30585577 | 0.94 | OPRM1 (0.48) | OPRM1OPRK1DRD1GNRHRMRGPRX2 | |
| SCHEMBL30440639 | 0.88 | OPRM1 (0.47) | OPRM1OPRK1NMUR2NMUR1APLNR | |
| SCHEMBL30440642 | 0.88 | OPRM1 (0.47) | OPRM1OPRK1NMUR2NMUR1APLNR | |
| SCHEMBL15892849 | 0.86 | OPRM1 (0.45) | OPRM1OPRK1CAPN1NMUR2NMUR1 | |
| Acetic Acid SCHEMBL30440885 | 0.86 | OPRM1 (0.48) | OPRM1OPRK1ABCB11NMUR2NMUR1 | |
| SCHEMBL29619531 | 0.86 | NPY4R (0.58) | OPRM1OPRK1DRD1GNRHRMRGPRX2 | |
| SCHEMBL29571998 | 0.84 | OPRM1 (0.48) | OPRM1OPRK1APLNR | |
| SCHEMBL8019005 | 0.83 | OPRM1 (0.60) | OPRM1OPRK1DRD1GNRHRMRGPRX2 | |
| SCHEMBL29421084 | 0.83 | OPRM1 (0.52) | OPRM1OPRK1NMUR2NMUR1 | |
| SCHEMBL29557983 | 0.83 | OPRM1 (0.49) | OPRM1OPRK1NMUR2NMUR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11180533-B2 | Process for the preparation of Cetrorelix acetate | BIOPHORE INDIA PHARMACEUTICALS PRIVATE LIMITED (IN) | 2021-11-23 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11180533-B2 | Process for the preparation of Cetrorelix acetate | CYP51A1, CYP17A1, CYP11A1 | OPRM1 463/4885OPRK1 109/4885DRD1 1667/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.